Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-687-1 | CAS number: 162303-51-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Study period:
- August 19, 1985 to November 26, 1985
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- The study was conducted in accordance with standard operating procedure of Toxicity Research Laboratory (TRL) with Compliance of GLP but do not specify guideline followed.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Four groups of male and female Sprague-Dawley rats (30/sex/group) were administered daily 0, 30, 125 or 500 mg/kg bw/day for either 6 or 13 weeks.
- GLP compliance:
- yes
Test material
- Reference substance name:
- Butan-1-ol
- EC Number:
- 200-751-6
- EC Name:
- Butan-1-ol
- Cas Number:
- 71-36-3
- Molecular formula:
- C4H10O
- IUPAC Name:
- 1-Butanol
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material: n-Butanol:
- Physical state: liquid
- Analytical purity: 99.9%
- Purity test date: feb 12, 1985
- Lot/batch No.: 3597 KVVE
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charls River Breeding laboratory, Inc., Portage, Michigan
- Age at study initiation: 22-23 days
- Weight at study initiation: 45-55 gram
- Diet (e.g. ad libitum): Purina certified Rodent laboratory chow #5002 (pellet)
- Water (e.g. ad libitum): Filtered municple water, analyzer periodically for the presence of contaminants as defined by EPA.
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 70.2 ± 2.2
- Humidity (%): 47.6±9.2
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: August 12, 1985 To: november 25 and 26, 1985
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test substance analysis was done by Gas chromatography -Hewlett Packard 5880 with automated sampler and varian flame ionization detector is used with following standard set
Injector Temperature : 150 ̊C
column Temperature : 140 ̊C isothermal
carrier flow : 25 ml/main N2
injection volume: 2 µl - Duration of treatment / exposure:
- 6 weeks exposure for 10 animals per group for interim sacrifice and 13 weeks exposure for final sacrifice.
- Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 30, 125, 500 mg/kg/day
Basis:
no data
- No. of animals per sex per dose:
- 30 animals per sex per dose in four group and 10 animals per sex per dose for fifth group
- Control animals:
- yes
- Details on study design:
- The amounts administered were based the most recent individual weekly body weight values.
N-Butanol Animals number (sacrifice)
Group Dose(mg/kg /day) male Female
interim final interim final
I 0 10 20 10 20
II 30 10 20 10 20
III 125 10 20 10 20
IV 500 10 20 10 20
V Base Line 10 20 10 20
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily
Cage side observations include clinical in File 1( attached below) were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes / No / No data
- Time schedule for examinations:
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: during pretreatment and on week 13
- Dose groups that were examined: all groups
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to treatment and on the time of nacropsy
- Anaesthetic used for blood collection: Yes (carbon dioxide)
- Animals fasted: No data
- How many animals: 10 animals per sex per dose group
- Parameters checked in File 2 (attached below) were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to treatment from dose group V and on the time of nacropsy
- Animals fasted: No data
- How many animals: 10 animals per sex per dose group
URINALYSIS: Yes
- Time schedule for collection of urine: prior to treatment from dose group V and 3-5 days prior to sacrifice
- Metabolism cages used for collection of urine: Yes, for 4 hours
- Animals fasted: No data
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
HISTOPATHOLOGY: Yes (see table) - Statistics:
- The body weight, food consumption, clinicopathologic, and organ weight data were tested for homogeneity of variance by Bartlett's method. If data were found to be homogeneous difference between control and treatment means were tested for statistical significance by method of Dunnett.If data not found to be homogeneous, The method of Gill (modified Dunnett's ) was employed.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment related ataxia first appeared in the high dose group during week 8. Ataxia and hyperactivity occurred in frequently during weeks 9 and 10. These sign increased to a weekly incidence of 32% and 29% for atxia and hypoactivity respectively. On set of ataxia and hyperactivity was about 2-3 minutes after dosing and duration was less then one hour.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Treatment related ataxia first appeared in the high dose group during week 8. Ataxia and hyperactivity occurred in frequently during weeks 9 and 10. These sign increased to a weekly incidence of 32% and 29% for atxia and hypoactivity respectively. On set of ataxia and hyperactivity was about 2-3 minutes after dosing and duration was less then one hour.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related effect was present on body weight and weight gain.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related effect was present on food consumption. Statistically significant difference between control and treated group and food consumption would occur sporadically,but no trend was observed.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Total Lesions 1, 2, 4, 5 ( including chorioretinal hypoplasia) were seen as in Control, Low dose, mid dose, high dose, respectively.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At interim sacrifice, RBC(p≤ .05), PCV and HCB,(p ≤.01) in high dose female were 5% less than thr control group. The RBC and PCV (p≤ .05) average for middle dose were also slightly ( 4% and 3% respectively) than control over ages.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At interim sacrifice, lower cholesterol level (p≤ .05) in high dose males, higher neutrophill count (p≤ .05) in mid dose male and at final evaluation lower lymphocyte count(p≤ .05) , higher neutrophill count in low dose females were observed.
- Endocrine findings:
- not examined
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Higher (p≤ .05) urine pH values in the low dose males at the interim evaluation and in low dose females at the final evaluation were observed.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- No apparent treatment related effect on organ weight value. The only statistically significant difference between control and high dose males was slightly(p≤ .05) higher thyroid weight. No dose response relationship was present.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related lesion was observed in gross necropsy at the interim or final sacrifices or of the rats found dead or sacrificed in extremes.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related lesion was observed at histopathologic evaluation. The diffuse subacute lymphadenitis of mendibular lymph node was visible grossly as red or enlarged lymph nodes. This is a commonly observed lesion in laboratory rats.
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- At interim evaluation, RBC, PCV, and HGB averages in the high dose females were 5% below control averages. The difference were statistically significant but biologically significance is questionable.
HISTOPATHOLOGY: NON-NEOPLASTIC . - Parameters checked in File 4 (attached below) were showing incidence of lesion examined.
BODY WEIGHT AND WEIGHT GAIN: change in mean organ weight were examine as shown in file 3(attached below)
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 125 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- haematology
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Read-across justifications and data matrices are presented in IUCLID section 13.
Applicant's summary and conclusion
- Conclusions:
- Oral administration of normal butanol at 500 mg/kg/day produced ataxia and hyperactivity at maximum weekly incidence rate of 32% and 29% respectively. A slightly lower (compare to controls) RBC, PCV and HGB concentration present in the 500 mg/kg/day dose group females at the interim evaluation only may have been treatment related. No treatment related effect were observed at 30 mg/kg/day and 125 mg/kg/day.
- Executive summary:
Based on the study results NOAEL was concluded to be 125 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies